Ocul Immunol Inflamm. 2010 Jan;18(1):46-51. doi: 10.3109/09273940903402637.
To report the clinical profile and management of patients diagnosed to have ampiginous choroiditis in a tertiary care referral centre in India.
Retrospective cohort study. Twenty-six eyes of 16 patients were included in the study, which was diagnosed as choroiditis, serpiginous choroiditis, and acute posterior multifocal placoid pigment epitheliopathy (APMPPE) or ampiginous choroiditis. Those who were initially diagnosed as having other forms of choroiditis were later classified as having ampiginous choroiditis clinically. Systemic steroids and immunosuppressives were the mainstay of therapy.
There was a male preponderance (7:3). Age at presentation ranged from 22 years to 57 years with a (median 34 years); 81% had bilateral involvement and 35% had recurrences. Vision improved or maintained in 24 eyes, whereas it deteriorated in 2 eyes due to subretinal fibrosis and macula involvement, respectively. Resolution of lesions and improvement or stability of vision can occur with administration of timely steroids and immunosuppressive therapy. Regular follow-up is necessary to monitor the disease progression, recurrences, and involvement of the other eye.
Ampiginous choroiditis is a separate disease entity due to its distinct clinical features. It is a disease with multiple relapses, which can be effectively controlled with a combination of immunosuppressive therapy, and a good visual acuity can be maintained on long-term follow-up.
报告在印度一家三级医疗转诊中心诊断为ampiginous 脉络膜炎患者的临床特征和治疗方法。
回顾性队列研究。本研究纳入了 16 名患者的 26 只眼,这些患者被诊断为脉络膜炎、匐行性脉络膜炎、急性后部多灶性脉络膜视网膜炎(APMPPE)或ampiginous 脉络膜炎。最初被诊断为其他类型脉络膜炎的患者后来被临床诊断为ampiginous 脉络膜炎。全身皮质类固醇和免疫抑制剂是主要的治疗方法。
男性居多(7:3)。发病年龄为 22 岁至 57 岁,中位数为 34 岁;81%为双侧受累,35%有复发。24 只眼的视力改善或保持不变,而由于视网膜下纤维化和黄斑受累,2 只眼的视力分别恶化。及时给予皮质类固醇和免疫抑制治疗可使病变消退,视力改善或稳定。需要定期随访以监测疾病进展、复发和另一只眼的受累情况。
ampiginous 脉络膜炎因其独特的临床特征,是一种独立的疾病实体。它是一种多复发疾病,联合免疫抑制治疗可有效控制,长期随访可保持良好的视力。